Medivir

A research based specialty pharmaceutical company focused on infectious diseases

EASL Breakfast 21 April 2012

Rein Piir EVP Corporate Affairs & IR Charlotte Edenius EVP R&D Bertil Samuelsson CSA

Medivir in a nutshell

- strong momentum in all parts of the company

- World class expertise in polymerase and protease drug targets Strong pipeline of innovative infectious disease drugs
- > All major projects are moving with a high momentum
- Medivir has a strong position in HCV drug development, four programs including all 3 validated target classes, two in-house driven
- ➤ 15 marketed products in the Nordics generating annual sales of €60 m with an EBITDA of ~€12 m




Strong financial position, aiming for profitability in a few years

Our aim is to become a profitable research-based specialty pharmaceutical company with main focus on infectious diseases, which creates value for our shareholders and enhances patients' quality of life



Strong platform for a leading position in hepatitis C



Aedivir

Strongly committed to innovation driven R&D - developing novel antivirals

Building on a longstanding protease inhibitor development experience

Two major internal cathepsin inhibitor programs:


Cathepsin K:

- Osteoarthritis, osteoporosis and metastatic bone disease
- Candidate drug selected, MIV-711
- Anticipated low QD dosage in man
- Regulatory safety documentation finalized and clinical trial application submitted
- Phase I to start in Q2 2012

Cathepsin S:

- Neuropathic pain and autoimmune diseases
- Potent, selective and orally bioavailable inhibitors developed
- Proof-of-principle demonstrated in a rodent model of neuropathic pain
- Late optimization phase aiming for candidate drug selection 2012







Strong commitment in hepatitis C – four major programs on-going

Polymerase inhibitor – nucleotide NS5B inhibitor

- Properties similar to the most advanced clinical nucleotides
- Both purines and pyrimidines
- High potencies in the replicon assay
- High triphosphate levels and long triphosphate t1/2 in human hepatocytes
- No observed cytotoxicity
- Aiming for Candidate Drug selection in Q4, 2012

NS5A inhibitor

- A next generation NS5A inhibitor with high barrier to resistance in preclinical phase
- Preclinical optimization phase

Polymerase inhibitor – nucleotide NS5B inhibitor Johnson Johnson V tibotec

•Liver targeted nucleotide polymerase inhibitor program as part of existing partnership

•Clinical Drug candidate selected and IND preparatory activities on-going




Internal - unpartnered projects

Strong commitment in hepatitis C – four major programs on-going

Protease inhibitor – TMC435

- Investigational, one pill, once daily, oral HCV protease inhibitor
- Potent antiviral activity in patients infected with HCV genotype 1
- Antiviral activity demonstrated against genotypes 1, 2, 4, 5, and 6 isolates
- Favorable safety profile
- Currently in Phase III clinical development





TMC435, triple combination therapy with PegINF/RBV

- summary phase IIb data

Best-in-class potential based on Phase II data

• Safe and efficacious with excellent tolerability (150 mg, q.d., 12 w)

Study	Patient population	SVR24
PILLAR	Treatment naive	81 - 86%
DRAGON	Treatment naive (Japan)	82%
ASPIRE	Relapsers	85%
	Partial responders	75%
	Null responders	51%

Efficacious in broad HCV patient populations


- G1 population, the most prevalent and difficult-to-treat
 - o Treatment naïve and treatment experienced patients
 - o Cirrhotic and non-cirrhotic patients

Robust clinical efficacy data, and large safety data base with approximately 1800 patients treated today



ASPIRE study:

A Phase IIb, randomised, double-blind clinical trial in treatment experienced HCV genotype 1 infected patients (n=462)



TMC435 either 100 or 150 mg QD

- Primary endpoint: SVR24
- Key secondary endpoints: Virologic response at other time points, viral breakthrough and relapse rates, safety and tolerability




ASPIRE study:

baseline demographics and disease characteristics

	TMC435 150 mg* PR48, n=199	Pbo PR48, n=66
Patient demographics		
Male, %	68	64
Race, White, %	93	94
Age, years, median (range)	50	50
Body weight, kg, median (range)	80.5	84.8
IL28B genotype CC†, %	17 (n=142)	22 (n=50)
Disease characteristics		
Genotype 1a, %	42	41
HCV RNA ≥800 000 IU/mL at baseline, %	85	83
Metavir Score, F3 / F4, %	15 / 20	20 / 16
ALT 2.5x-10x>Upper Limit of Normal, %	17 / 2	12 / 5



ASPIRE study: proportion of patients achieving SVR24 by prior response



All patients

62 % of patients (287/462) had advanced liver disease (Metavir F2-F4)



*Dose groups (treatment duration) combined;

ASPIRE study: Proportion of patients achieving SVR24 by prior response


100 Propertions of gatients achieving SVR248% Relapsers **Partial responders Null responders** 94 79 66 **56** 23 Pho TMC435 TMC435 TMC435 Pbd Pho **PR48 PR48 PR48** 150mg* 150mg* 150mg* **PR48 PR48 PR48** 52 12 29 16 48 13 n=

Metavir: F0-F2



ASPIRE study: Proportion of patients achieving SVR24 by prior response

Cirrhotics (F4)





*Dose groups (treatment duration) combined;

ASPIRE study:

adverse events

Note: mean PegIFN/RBV exposure longer for patients in TMC435 groups (41 weeks) compared with placebo group (28 weeks)

	TMC435 150 mg* n=199	Pbo PR48 n=66	
AEs leading to TMC435/Pbo discontinuation, %	9	5	
Serious adverse events, %	10	6	
Grade 3-4 AEs	36	26	
AEs most frequently reported inTMC435 groups (>	25% of patients), 9	%	
Headache	40	36	
Fatigue	41	44	
Influenza-like illness	24	20	
Pruritus	35	17	
Neutropenia	28	17	
AEs of interest (regardless of severity or causality), %		
Hepatobiliary disorders	10	5	
Rash (any type) [†]	30	18	
Rash (any type), Grade 3	0.5	0	
Photosensitivity AEs	6	2	



ASPIRE study:

summary

- With TMC435 150 mg in combination with PegIFN/RBV:
 - 85% of prior relapsers achieved SVR24
 - 75% of prior partial responders achieved SVR24
 - 51% of prior null responders achieved SVR24
 - 73, 82, 31% in patients with cirrhosis (relapsers, partials, nulls)
- Once-daily TMC435 was well tolerated in this population

TMC-435: Best-in-class properties in triple combination standard of care treatment



TMC435 - triple combination

broad phase III clinical development program in genotype-1

QUEST 1 treatment-naïve patients; n=375 QUEST 2 treatment-naïve patients; n=375 PROMISE (C3007) prior relapsed patients; n=375 Japan naïve & experienced patients; n=417 (four studies)

Fully enrolled Q3-11, all patients have finished their TMC435 treatment

Regulatory filings in first half of 2013 in US, EU and Japan



TMC435 - triple combination

continued clinical development program

Selected ongoing studies:

C3001 comparing <u>TMC435 vs telaprevir</u>, in prior null or partial responders; *n*=744

C3011 open label, single arm phase III trial in treatment naïve or treatment experienced, HCV genotype-4 infected patients; *n*=100

C212 open-label study in patients <u>co-infected with HIV</u>; *n*=94

Strong commitment from our partner Janssen Pharmaceuticals



TMC435 – interferon free combinations

TMC435 and GS-7977 (nucleotide NS5B inhibitor)

-genotype 1 prior null responders, non-cirrhotic and cirrhotic patients, n=180

-12 and 24 weeks treatment durations, +/- RBV

-On-going


TMC435 and daclatasvir (NS5A inhibitor), clinical phase II and III collaboration –genotype 1 null responder and interferon intolerant patients –12 and 24 weeks treatment durations, +/- RBV –Planned to start H1-2012

TMC435 and BMS-986094 (former INX-189; a nucleotide NS5B inhibitor) –*Clinical evaluation will start with a DDI study*

TMC435, a best in class PI, strongly positioned to become the principal component of future IFN-free therapies



Strong platform for a leading position in hepatitis C





Hepatitis C – Treatment evolution

INF-free combinations delivers promise in early phase II trials

Bertil Samuelsson, CSA



Evolution of HCV therapy

DAA combinations, INF-free and INF /RBV-free, are now evaluated in phase II clinical trials

Lessons learned from 1, 2 or 3 DAAs (+/- ribavirin)

- Proof-Of-Concept achieved
- Cirrhotic patient data are largely missing. These patients are the most difficult to treat and make up a substantial portion on the available patient pool
- SVR36 might be needed to capture real life relapse rates in an IFN-free setting

Ribavirin will not be part of future HCV combinations

- · Ribavirin has severe side effects and safety issues
- Can cause severe adverse events in patients, e.g. hemolytic anemia, teratogenicity, cough, dyspnea, rash, pruritus, insomnia and anorexia. It is a powerful mutagenic agent and is contraindicated in pregnant women and patients with hemoglobinopathies



Evolution of HCV therapy

Goals for next generation standard of care treatment s

- 2 DAAs in a combination potential to meet cost and reimbursement challenges of the future
- Compelling efficacy, strong safety and minimal side effects
- 12 weeks treatment duration
- Fixed dose combination and once daily



Patient responses to treatment – a complex picture

- Genotype/subtype
- Liver disease, F4-F0

4

- Population
- IL28B at baseline
- Patient characteristics
 - Treatment experienced
 - Treatment naïves

Most difficult to treat		Highest treatment responses
G1a G1b	G4/6	G3 G2
F4 F3		Non-cirrhotic (F2, F1 & F0)
Blacks	Hispanic	Caucasian
TT	СТ	CC
null responde	r partial responder	relapser
		treatment naïve

Treatment experienced	% F4	% F3-4
ASPIRE	18	37

TM435 has in the three large phase IIb trials been addressing the most difficult to treat patients



IFN + RBV-free combinations – first proof-of-concept achieved

Two DAAs only

– BMS daclatasvir + asunaprevir

Cirrhotic patients NO

- o 90% SVR12, 24 weeks, G1b null responders (Japan), patients, n= 21
- o 64% SVR12, 24 weeks, G1b IFN ineligible or intolerant (Japan), patients, n=22
- BMS daclatasvir + asunaprevir

Cirrhotic patients NO

- o 36% SVR12, 24 weeks, G1 null responders (64% RVR), n=11
- BMS daclatasvir + GS-7977
 Cirrhotic patients
 NO
 - 100% SVR4 (SVR12 considered as cure rate), 24 weeks , (n=29), G1 treatment naïve patients



IFN-free combinations - proof-of-concept achieved

Combination: Two DAAs + ribavirin

- BI-201335 + BI-207127 + RBV

o SVR12 60%, 16 weeks, G1 treatment naïve patients (SOUND-C2)

- ABT-450 + ritonavir + ABT-333 + ribavirin Cirrhotic patients NO
 - SVR12 93%(n=14); 95%(n=19), 12 weeks, G1 treatment naïve, non-cirrhotic patients
 - SVR12 47%, (n=17), 12 weeks, non-responders (6 null & 11 partial resp.), noncirrhotic patients
- ABT-450 + ritonavir + ABT-072 + ribavirin Cirrhotic patients NO
 - 82% SVR36, 12 weeks, G1 treatment naïve non-cirrhotic patients, IL28B CC genotype

A protease inhibitor present in all these combinations



IFN-free combinations - proof-of-concept achieved

One DAA + ribavirin

- GS-7977 + RBV Cirrhotic patients NO

○ SVR4 11%, 12 weeks in G1 null responders (n=9) ELECTRON trial

o SVR4 88%, 12 weeks, G1 treatment naïves (n=25), ELECTRON trial

– GS-7977 + RBV

Cirrhotic patients Yes

o SVR4 59%, 12 weeks, G1 treatment naïves (10/17), QUANTUM trial

One nucleotide DAA + RBV - likely suboptimal combination



TMC 435 - summary


A best-in-class triple combination - TMC435 + P/R

Broad label and expected on the market by end of 2013 in e.g. EU, US and JPN

- Long patent life, IP extending to 2026 and 2028
- Safe and well tolerated very important for treatment compliance once on the market
 - Close to 1800 patients have completed TMC435 treatments showing it to be safe and well tolerated
 - Over 1000 additional patients are currently being recruited
- 24-Week duration of treatment in both naïve and in experienced prior relapser patients (response guided)
- Highly efficacious in; a) G1a and G1b, b) treatment naïve and treatment experienced, c) cirrhotic and non-cirrhotic patients, d) regardless of IP-10 level or *IL28B* genotype, i.e. CC, CT or TT, as demonstrated in three large phase IIb trials (PILLAR, ASPIRE and DRAGON)
- Low dose, one tablet once daily, 12 weeks of TMC435,150mg easy to remember and set up for a Fixed Dose Combination tablet
- Broad genotypic coverage



Strong platform for a leading position in hepatitis C



Expected key news flow highlights

- ✓ Q1-12 DAA phase II combination study with TMC435 and GS-7977 started
- ✓ Q1-12 OTC launch of Xerclear® (ZoviDuo) in Europe by GSK
- ✓ Q1-12 Start of Phase III trials with TMC435 + standard of care in prior null and partial responder patients vs telaprevir.
- ✓ Q2-12 Expanded agreement signed on TMC435 and daclatasvir (BMS-790052) collaboration
- ✓ Q2-12 TMC435 and BMS-986094 (formerly INX-189), two direct-acting antivirals in combination, will be evaluated in clinical trials
- ✓ Q2-12 EASL ASPIRE full SVR24 data
- ✓ Q2-12 Janssen creates new division to launch TMC435 in EMEA
- Q2-12 Start of DAA phase II combination study with TMC435 and daclatasvir
- Q2-12 Start of Phase I clinical trials with MIV-711 (cathepsin K inhibitor)
- Q4-12 Potential CD selection in our internal Nucleotide NS5B inhibitor program
- Q4-12 EoT-data from Cohort 1 with TMC435 and GS7977 DAA phase II study
- Q4-12 Potential CD selection in Cathepsin S (Neuropathic pain) program
- Q4-12 Goal to start phase 1 trials with Medivir/Janssen Nucleotide NS5B inhibitor
- Q4-12 Top line results from phase III trials with TMC435 (Quest 1+2 and Promise)

